INCY vs. MEDP, CRL, PRAH, PPD, BIIB, ALNY, BMRN, NBIX, UTHR, and EXAS
Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Medpace (MEDP), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PPD (PPD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
Medpace (NASDAQ:MEDP) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
Medpace presently has a consensus target price of $443.14, suggesting a potential upside of 14.70%. Incyte has a consensus target price of $73.69, suggesting a potential upside of 27.51%. Given Medpace's higher probable upside, analysts plainly believe Incyte is more favorable than Medpace.
Incyte has a net margin of 19.78% compared to Incyte's net margin of 15.92%. Incyte's return on equity of 59.74% beat Medpace's return on equity.
In the previous week, Medpace had 12 more articles in the media than Incyte. MarketBeat recorded 21 mentions for Medpace and 9 mentions for Incyte. Medpace's average media sentiment score of 1.20 beat Incyte's score of 0.73 indicating that Incyte is being referred to more favorably in the news media.
Incyte has higher revenue and earnings than Medpace. Incyte is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
78.0% of Medpace shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Comparatively, 17.5% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Medpace has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Incyte received 871 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 73.58% of users gave Incyte an outperform vote while only 64.14% of users gave Medpace an outperform vote.
Summary
Medpace and Incyte tied by winning 9 of the 18 factors compared between the two stocks.
Get Incyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
